Evidence for distinct endothelin receptors in the pulmonary vascular bed in vivo

• Published in: Journal of cardiovascular pharmacology Vol. 17 Suppl 7; p. S370
• Main Authors: Lippton, H L, Cohen, G A, Knight, M, McMurtry, I F, Gillot, D, Arena, F, Summer, W, Hyman, A L
• Format: Journal Article
• Language: English
• Published: United States 1991
• Subjects: Animals; Blood Pressure - drug effects; Cats; Endothelins - antagonists & inhibitors; Endothelins - metabolism; Endothelins - pharmacology; Lung - blood supply; Muscle, Smooth, Vascular - chemistry; Pulmonary Circulation - drug effects; Receptors, Cell Surface - analysis; Receptors, Endothelin; Tachyphylaxis - physiology; Vascular Resistance - drug effects; Vasodilation - drug effects
• ISSN: 0160-2446
• DOI: 10.1097/00005344-199100177-00105

The present study was undertaken to investigate the effects of endothelin (ET) isopeptides on the pulmonary vascular bed of the intact, spontaneously breathing cat under conditions of constant pulmonary blood flow and left atrial pressure. When pulmonary vasomotor tone was actively increased by intralobar infusion of U46619, intralobar bolus injections of ET-1 (1 micrograms), ET-2 (1 micrograms), and ET-3 (3 micrograms) produced marked reductions in pulmonary and systemic vascular resistances. The pulmonary vasodilator response to each ET isopeptide was not altered by atropine (1 mg/kg i.v.), indomethacin (2.5 mg/kg i.v.), or ICI 118551 (1 mg/kg i.v.), but was significantly inhibited by an intra-arterial (i.a.) infusion of glybenclamide at 5 mg/kg. This dose of glybenclamide significantly inhibited the decrease in lobar arterial and systemic arterial pressures in response to intralobar injection of pinacidil (30 and 100 micrograms), whereas the pulmonary vasodilator responses to acetylcholine (0.03 and 0.1 micrograms) and prostaglandin I2 (0.1 and 0.3 micrograms) were not altered. The systemic vasodilator response to each ET isopeptide was not changed by glybenclamide or by the other blocking agents studied. The present data demonstrate for the first time that ET-1, ET-2, and ET-3 dilate the pulmonary vascular bed in vivo. The present data suggest that the pulmonary vasodilator response to ET isopeptides depends, in part, on activation of potassium channels and is mediated differently from the systemic vasodilator response to these substances. Contrary to earlier work, the present data indicate the pulmonary vascular response to ET isopeptides depends on the pre-existing level of pulmonary vasomotor tone. Furthermore, the present data suggest that in the lung ET-1, ET-2, and ET-3 may serve as endogenous agonists for potassium channels, a newly described vasodilator mechanism in the pulmonary vascular bed of intact adult animals.